New treatment strategies in advanced neuroendocrine tumours.

Dig Liver Dis

Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Lyon CEDEX 03, France.

Published: February 2012

Malignant well-differentiated neuroendocrine tumours of the pancreas and the gastrointestinal tract are rare and clinically challenging heterogeneous neoplasms. This review focuses on neuroendocrine tumours grade 1 and grade 2 (new WHO classification 2010), in comparison to the neuroendocrine tumours grade 3 group, corresponding to poorly differentiated neuroendocrine carcinomas. Surgical resection of the primary and metastases remains the only curative treatment, however many patients with neuroendocrine tumours are diagnosed once unresectable metastases have occurred; management of functioning syndromes with somatostatin analogues remains the priority. Pasireotide, a new somatostatin analogue, is currently undergoing evaluation for carcinoid syndrome. Treatment options for advanced neuroendocrine tumours differ from pancreatic gastrointestinal tract neuroendocrine tumours: (a) in pancreatic neuroendocrine tumours, streptozotocin-based chemotherapies are challenged by other cytotoxic agents (dacarbazine, temozolomide and oxaliplatin); two randomized, placebo-controlled phase III studies have demonstrated that everolimus and sunitinib significantly improved progression-free-survival; (b) in midgut neuroendocrine tumours, octreotide improved time-to-progression in patients with a low proliferation index and low liver burden; preliminary data suggesting efficacy of bevacizumab are still to be confirmed; the effect of everolimus associated with octreotide was almost significant on progression-free-survival in a phase III trial. Liver-directed therapies are effective in both tumour types. New techniques of embolization need further evaluation and must be formally compared to other therapies. Finally, peptide receptor radionuclide therapy has shown promising activity in non-comparative studies in advanced neuroendocrine tumours.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2011.08.022DOI Listing

Publication Analysis

Top Keywords

neuroendocrine tumours
40
advanced neuroendocrine
12
neuroendocrine
11
tumours
10
gastrointestinal tract
8
tumours grade
8
phase iii
8
treatment strategies
4
strategies advanced
4
tumours malignant
4

Similar Publications

There are numerous versions of octreotide and octreotate, including DOTAMTATE, DOTATATE, JR11, and lead-specific chelator (PSC)-PEG2-TOC. These peptides, which can be either analogs or antagonists, are used in nuclear medicine for diagnostic imaging or targeted radionuclide therapy of neuroendocrine tumors that are positive for somatostatin receptors (SSTRs). Despite their structural and targeting similarities, they have distinct properties and clinical uses.

View Article and Find Full Text PDF

Spinal extramedullary tumors are the most common types of schwannomas and meningiomas. Therefore, most spinal cord surgeons should safely perform surgeries for these tumors. The posterior approach with conventional laminectomy is sufficient for the safe resection of almost all spinal extramedullary tumors.

View Article and Find Full Text PDF

Cervical sympathetic paraganglioma: A rare case managed with embolization and surgery with successful nerve recovery.

Int J Surg Case Rep

January 2025

University Hospital Center "Sestre Milosrdnice", Department for Diagnostic and Interventional Radiology, Vinogradska cesta 29, 10000 Zagreb, Croatia; University Hospital Center "Sestre Milosrdnice", Department of Otorhinolaryngology and Head and Neck Surgery, Vinogradska cesta 29, 10000 Zagreb, Croatia.

Introduction And Importance: Sympathetic paragangliomas are rare neuroendocrine tumors arising from the sympathetic nervous system.

Case Presentation: We present a case of a 48-year-old woman with an extremely rare paraganglioma arising from the cervical sympathetic chain that was presented to the emergency department with symptoms of respiratory insufficiency and dysphagia. Imaging revealed a highly vascularized tumor originating from the jugular fossa.

View Article and Find Full Text PDF

Prognostic value of immune biomarkers in melanoma loco-regional metastases.

PLoS One

January 2025

Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway.

The prognosis for patients with melanoma loco-regional metastases is very heterogenous. Adjuvant PD-L1-inhibitors have improved clinical outcome for this patient group, but the prognostic impact of tumour PD-L1 expression and number of tumour infiltrating lymphocytes (TILs) is still largely unknown. Here, we investigated the impact on survival for CD3, CD8, FOXP3 and PD-L1 TIL counts and tumour PD-L1 expression in melanoma loco-regional metastases.

View Article and Find Full Text PDF

Background: Patients with melanoma receiving immunotherapy with immune-checkpoint inhibitors often experience immune-related adverse events, cancer-related fatigue, and emotional distress, affecting health-related quality of life (HRQoL) and clinical outcome to immunotherapy. eHealth tools can aid patients with cancer in addressing issues, such as adverse events and psychosocial well-being, from various perspectives.

Objective: This study aimed to explore the effect of the Cancer Patients Better Life Experience (CAPABLE) system, accessed through a mobile app, on HRQoL compared with a matched historical control group receiving standard care.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!